Crescent Biopharma Inc CBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
-
Crescent Biopharma Announces Grants of Inducement Awards
-
Crescent Biopharma Receives FDA Clearance for Investigational New Drug Application
-
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
-
Crescent Biopharma Announces Grants of Inducement Awards
-
Crescent Biopharma Announces Grants of Inducement Awards
-
Crescent Biopharma to Present at September Investor Conferences
-
Crescent Biopharma Announces Grants of Inducement Awards
Trading Information
- Previous Close Price
- $12.48
- Day Range
- $11.78–12.73
- 52-Week Range
- $8.72–27.41
- Bid/Ask
- $11.82 / $13.37
- Shares Outstanding
- 37.15M
- Market Cap
- $439.82M
- Volume/Avg
- 208,178 / 368,937
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 44
Valuation
|
Metric
|
CBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.25 |
Price/Sales | 26.60 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CBIO
|
|---|---|
Quick Ratio | 9.26 |
Current Ratio | 9.66 |
Interest Coverage | — |
Quick Ratio
CBIO
Profitability
|
Metric
|
CBIO
|
|---|---|
Return on Assets (Normalized) | −81.88% |
Return on Equity (Normalized) | −95.62% |
Return on Invested Capital (Normalized) | −95.61% |
Return on Assets
CBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|W@T?n?# | LOCK|&>rz | $127B | |||
| Moderna Inc
MRNA
| LOCK|@@#QC< | LOCK|!g | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%@&Y&h | LOCK|&mTV | $81B | |||
| argenx SE ADR
ARGX
| LOCK|!sS@>R | LOCK|Jw | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s#L!^$ | LOCK|Jd$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>#Mmcz | LOCK|^!Xcp | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>$CB?@P< | LOCK|^hY#? | $27B | |||
| Incyte Corp
INCY
| LOCK|g<#tHCT | LOCK|bg | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|R??Y!? | LOCK|>ww | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Q%BHc$ | LOCK|^kB | $14B |
United States